Chair: David Haerry

Axel Mühlbacher

Patient Involvement in Healthcare Decision Making: Is there a rationale for considering patient preferences?
Institute for Health Economics and Health Care Management, Hochschule Neubrandenburg, Germany & Duke University, USA

Axel Mühlbacher is professor of health economics and health care management at Hochschule Neubrandenburg. As a secondary appointment he is an adjunct professor in the Duke Department of Population Health Sciences, and a CHPIR Senior Research Fellow in the Center for Health Policy and Inequalities Research at the Duke Global Health Institute, Duke University (USA). He serves as a member of the scientific advisory board of the Institute for Quality Assurance and Transparency in Healthcare (IQTiG) and a board member and chair of the International Academy of Health Preference Research (IAHPR). He currently serves as associate editor of Value in Health and on the editorial advisory board of the Journal of Choice Modelling (JOCM), PharmacoEconomics, Int. Journal of Integrated Care (IJIC) and The Patient – Patient Centered Outcomes Research. Axel Mühlbacher is author of several books and more than 100 peer-reviewed articles.

Anne Böhmer representing Wiebke Löbker

Strengthening Training in Academia in Regulatory Sciences – Introduction into CSA STARS
Head of Unit Innovation, Change management / Personal advisor to the president of the BfArM Federal Institute for Drugs and Medical Devices, Germany

Panel Discussion:
Axel Mühlbacher, Hochschule Neubrandenburg, Germany & Duke University, USA
Anne Böhmer, BfArM, CSA STARS, Germany
Serena Scollen, ELIXIR

Serena Scollen

ELIXIR, Intergovernment Organisation

Serena is the Head of Human Genomics and Translational Data at ELIXIR, the European infrastructure for bioinformatics and life-science data, based in Hinxton, UK. Her vision is to ensure data that can be shared, will be shared responsibly. She is working with scientists across Europe to establish standards and infrastructure to facilitate discoverability, access, sharing and analysis of genomics data, linked to other data types and at a scale that has not previously been achieved. Developing infrastructure will unleash new possibilities for genomics and health. Serena is the coordinator of the B1MG project, a €4M EU H2020 Coordination and Support Action that is aligned with the 1+ Million Genomes Initiative (1+MG). This initiative is a commitment of 24 European countries to give cross-border access to one million sequenced genomes by 2022. She is also project lead for the Innovative Medicine Initiative (IMI) FAIRplus project, an €8.3M collaboration that sets out to improve data sharing and reuse in life science research. Prior to joining ELIXIR, she was a Director within the Human Genetics and Computational Biomedicine group at Pfizer. In this role, she led and implemented a genetic and precision medicine strategy to support drug target selection and clinical programmes for the Pain and Sensory Disorders Research Unit. She was also a member of the ABPI Stratified Medicine Working Group. Earlier in her career, she worked within the Toxicogenomics group at GlaxoSmithKline. She gained postdoctoral experience at the University of Cambridge and Imperial College London and a PhD from the University of Cambridge, with a focus on the genetic susceptibility to disease.